Analysis
Iambic Therapeutics set terms for a $150 million Nasdaq IPO at $15 to $17 a share this week, up sharply from the roughly $100 million it originally sought when it filed in September -- a 9.375 million-share offering implying a market cap of about $758 million. The company reported a $77.3 million net loss in 2025.
An upsized range between the initial S-1 and the terms-setting stage is a real signal, not routine paperwork. Underwriters don't widen a deal's target without investor demand surfacing during the roadshow process; a company that filed for $100 million and came back asking the market for 50% more is telling buyers it believes the appetite is there to support a bigger raise at a premium valuation.
“An upsized range between the initial S-1 and the terms-setting stage is a real signal, not routine paperwork.”
The timing makes the signal sharper. In the same stretch, Firmus, the Nvidia-backed data-center developer, withdrew its roughly $31 billion-valuation Australian IPO the day it was due to publish its prospectus. One company walked away from a mega-deal citing market turbulence; another used the same market to justify asking for more money than it originally planned. That's not a contradiction -- it's evidence that this market is pricing deal size and capital intensity, not broad "biotech" or "tech" sentiment, as the main variable.
Iambic's $77.3 million net loss for 2025 means the extra $50 million it's now seeking isn't just opportunism; it buys real runway at a company still burning meaningfully as it advances its pipeline. A bigger raise at a premium valuation is the best outcome a cash-burning biotech can hope for heading into a public listing, and it beats the alternative of pricing at the low end of a narrower range just to get the deal done.
The open question is how much of this is Iambic-specific versus a genuine re-opening of appetite for biotech IPOs generally. TRex Bio and Retension Pharmaceuticals both priced smaller deals in the same stretch, and neither needed an upsized range to get done -- which makes Iambic's revision the standout data point so far, not yet confirmation of a broader trend. The next few biotech listings to set terms will say whether this was a one-company story or the start of a pattern.